Cargando…
A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes
Dosing guidelines for patients with type 1 diabetes using continuous subcutaneous insulin infusion (CSII), which are historically based on clinical experience and retrospective studies of patients consuming an American diet, recommend that basal insulin should represent approximately 50 % of the tot...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960276/ https://www.ncbi.nlm.nih.gov/pubmed/27457238 http://dx.doi.org/10.1007/s11892-016-0772-0 |
_version_ | 1782444499881951232 |
---|---|
author | King, Allen B. Kuroda, Akio Matsuhisa, Munehide Hobbs, Todd |
author_facet | King, Allen B. Kuroda, Akio Matsuhisa, Munehide Hobbs, Todd |
author_sort | King, Allen B. |
collection | PubMed |
description | Dosing guidelines for patients with type 1 diabetes using continuous subcutaneous insulin infusion (CSII), which are historically based on clinical experience and retrospective studies of patients consuming an American diet, recommend that basal insulin should represent approximately 50 % of the total daily dose (TDD). Recent prospective studies in the USA and Japan conclude that the more appropriate proportion is closer to 30–40 % of TDD. In addition, currently used formulas for calculating the carbohydrate-to-insulin ratio (CIR) and correction factor (CF) may lead to underdosing of bolus insulin by as much as 12.8–50 % for a hypothetical patient. The discrepancies between traditional formulas and data from newer studies can be accounted for by the more rigorous design of the newer studies (e.g., prospective design, controlled diets, meal omission, and frequent glucose monitoring). International differences in diet composition may also be important to consider when developing dosing recommendations for CSII. |
format | Online Article Text |
id | pubmed-4960276 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-49602762016-08-08 A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes King, Allen B. Kuroda, Akio Matsuhisa, Munehide Hobbs, Todd Curr Diab Rep Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor) Dosing guidelines for patients with type 1 diabetes using continuous subcutaneous insulin infusion (CSII), which are historically based on clinical experience and retrospective studies of patients consuming an American diet, recommend that basal insulin should represent approximately 50 % of the total daily dose (TDD). Recent prospective studies in the USA and Japan conclude that the more appropriate proportion is closer to 30–40 % of TDD. In addition, currently used formulas for calculating the carbohydrate-to-insulin ratio (CIR) and correction factor (CF) may lead to underdosing of bolus insulin by as much as 12.8–50 % for a hypothetical patient. The discrepancies between traditional formulas and data from newer studies can be accounted for by the more rigorous design of the newer studies (e.g., prospective design, controlled diets, meal omission, and frequent glucose monitoring). International differences in diet composition may also be important to consider when developing dosing recommendations for CSII. Springer US 2016-07-25 2016 /pmc/articles/PMC4960276/ /pubmed/27457238 http://dx.doi.org/10.1007/s11892-016-0772-0 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor) King, Allen B. Kuroda, Akio Matsuhisa, Munehide Hobbs, Todd A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes |
title | A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes |
title_full | A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes |
title_fullStr | A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes |
title_full_unstemmed | A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes |
title_short | A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes |
title_sort | review of insulin-dosing formulas for continuous subcutaneous insulin infusion (csii) for adults with type 1 diabetes |
topic | Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960276/ https://www.ncbi.nlm.nih.gov/pubmed/27457238 http://dx.doi.org/10.1007/s11892-016-0772-0 |
work_keys_str_mv | AT kingallenb areviewofinsulindosingformulasforcontinuoussubcutaneousinsulininfusioncsiiforadultswithtype1diabetes AT kurodaakio areviewofinsulindosingformulasforcontinuoussubcutaneousinsulininfusioncsiiforadultswithtype1diabetes AT matsuhisamunehide areviewofinsulindosingformulasforcontinuoussubcutaneousinsulininfusioncsiiforadultswithtype1diabetes AT hobbstodd areviewofinsulindosingformulasforcontinuoussubcutaneousinsulininfusioncsiiforadultswithtype1diabetes AT kingallenb reviewofinsulindosingformulasforcontinuoussubcutaneousinsulininfusioncsiiforadultswithtype1diabetes AT kurodaakio reviewofinsulindosingformulasforcontinuoussubcutaneousinsulininfusioncsiiforadultswithtype1diabetes AT matsuhisamunehide reviewofinsulindosingformulasforcontinuoussubcutaneousinsulininfusioncsiiforadultswithtype1diabetes AT hobbstodd reviewofinsulindosingformulasforcontinuoussubcutaneousinsulininfusioncsiiforadultswithtype1diabetes |